Aclaris Therapeutics (ACRS) Other Non Operating Income (2016 - 2024)
Aclaris Therapeutics' quarterly Other Non Operating Income came in at $1.9 million in Q2 2024, down 16.83% year-on-year from $2.2 million in Q3 2023, and down 6.13% quarter-over-quarter from $2.0 million in Q1 2024.
Aclaris Therapeutics has reported Other Non Operating Income for 9 years, with the latest figure at $1.9 million in Q2 2024.
- For the quarter ending Q2 2024, Other Non Operating Income fell 16.83% year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2024 stood at $8.4 million (up 31.29% YoY), and the FY2023 full-year result was $8.5 million, up 188.83% from the prior year.
- Other Non Operating Income for Q2 2024 stood at $1.9 million, down from $2.0 million in the prior quarter.
- The five-year high for Other Non Operating Income was $2.3 million in Q3 2023, with the low at -$851000.0 in Q3 2021.
- Average Other Non Operating Income over 5 years is $763722.2, with a median of $320000.0 recorded in 2020.
- Year-over-year, Other Non Operating Income tumbled 338.66% in 2021 and soared 1522.47% in 2022.
- Tracing ACRS's Other Non Operating Income over 5 years: stood at -$219000.0 in 2020, then surged by 140.64% to $89000.0 in 2021, then jumped by 1522.47% to $1.4 million in 2022, then jumped by 51.59% to $2.2 million in 2023, then dropped by 14.66% to $1.9 million in 2024.
- The last three Other Non Operating Income figures came in at $1.9 million (Q2 2024), $2.0 million (Q1 2024), and $2.2 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Aclaris Therapeutics | 586.09 Mn | 586.09 Mn | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.87 Mn |
| Mar 31, 2024 | 1.99 Mn |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | 2.25 Mn |
| Mar 31, 2023 | 1.76 Mn |
| Dec 31, 2022 | 1.44 Mn |
| Sep 30, 2022 | 922,000.00 |
| Jun 30, 2022 | 462,000.00 |
| Mar 31, 2022 | 118,000.00 |
| Dec 31, 2021 | 89,000.00 |
| Sep 30, 2021 | -851,000.00 |
| Jun 30, 2021 | -155,000.00 |
| Mar 31, 2021 | -225,000.00 |
| Dec 31, 2020 | -219,000.00 |
| Sep 30, 2020 | -194,000.00 |
| Jun 30, 2020 | -189,000.00 |
| Mar 31, 2020 | 178,000.00 |
| Dec 31, 2019 | -1.90 Mn |
| Sep 30, 2019 | -274,000.00 |
| Jun 30, 2019 | -85,000.00 |
| Mar 31, 2019 | -230,000.00 |
| Dec 31, 2018 | 487,000.00 |
| Sep 30, 2018 | 710,000.00 |
| Jun 30, 2018 | 760,000.00 |
| Mar 31, 2018 | 719,000.00 |
| Dec 31, 2017 | 678,000.00 |
| Sep 30, 2017 | 564,000.00 |
| Jun 30, 2017 | 457,000.00 |
| Mar 31, 2017 | 371,000.00 |
| Dec 31, 2016 | 152,000.00 |
| Sep 30, 2016 | 118,000.00 |
| Jun 30, 2016 | 118,000.00 |
| Mar 31, 2016 | 100,000.00 |